Loading stock data…
TERUMO CORP (4543.T)
TSE¥2,327-47.00 (-1.98%)
Market ClosedLast close Sep 8
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Terumo Corporation in the Healthcare sector is trading at ¥2,326 with a market capitalization of $3.8T. Wall Street consensus targets ¥3,141 (13 analysts), implying a +35.0% move over the next 12 months. The stock is currently 13% below its 52-week high of ¥2,689, remaining 4.5% above its 200-day moving average. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Annual Financials
| Metric (JPY) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | ¥820.21B↓ | ¥921.86B↓ | ¥1.04T↓ | ¥1.13T |
| Gross Profit | ¥417.37B↓ | ¥479.17B↓ | ¥560.67B↓ | ¥594.67B |
| Operating Income | ¥117.33B↓ | ¥140.09B↓ | ¥157.67B↓ | ¥176.32B |
| Net Income | ¥89.33B↓ | ¥106.37B↓ | ¥116.98B↓ | ¥135.91B |
Peer Comparison
JNJUNHPFE
Fundamentals
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Sol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥3.83T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.18
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Strong income play. Yield provides a meaningful total return floor.
140.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.85%
Volume
Today's trading volume
3.94M
Recent News
Terumo Corp (TRUMF) (Q1 2027) Earnings Call Highlights: Record Revenue and Profit Surge on ...
Terumo Corp (TRUMF) posts record Q1 results with revenue up 9% locally and operating profit soaring 60%, driven by robust global demand and boosted by tariff refunds and settlement proceeds.
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
Terumo (TSE:4543) Valuation Check After Strong 2026 Earnings And Sharp Share Price Rebound
Terumo (TSE:4543) is back in focus after reporting full year results to March 31, 2026, with sales of ¥1,131,877 million and net income of ¥135,914 million, both higher than a year earlier. See our latest analysis for Terumo. The earnings release has been met with a sharp change in sentiment, with a 24.53% 7 day share price return and a 21.99% 90 day share price return contrasting with a 1 year total shareholder return that declined 9.96%. This suggests short term momentum is building after a...
Why Terumo (TSE:4543) Is Up 24.5% After Stronger Full-Year Earnings Lift Profitability - And What's Next
Terumo Corporation has reported past full-year results for the 12 months to March 31, 2026, with sales rising to ¥1,131.88 billion and net income reaching ¥135.91 billion, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year. The combination of stronger revenue and earnings indicates that Terumo improved its profitability over the period, suggesting that recent operational initiatives and cost controls have been effective. We’ll now...